PCSK9 and familial hypercholesterolemia: Indeed, a study directed by Barale et al., who followed up a 12-month treatment of anti-PCSK9 monoclonal antibodies (alirocumab or evolocumab) in patients affected by primary hypercholesterolemia with statin and aspirin treatment (n = 24), demonstrated that patients benefit from anti-PCSK9 mAb treatment [75].